Procoagulant activity of human neuroblastoma cell lines, in relation to cell growth, differentiation and cytogenetic abnormalities

Jpn J Cancer Res. 1989 May;80(5):438-43. doi: 10.1111/j.1349-7006.1989.tb02333.x.

Abstract

Procoagulant activity (PCA) was investigated in relation to cell growth, differentiation, and cytogenetics in seven human neuroblastoma cell lines. Before 5-bromodeoxyuridine (BrdUrd) treatment, PCA was notably heterogeneous, with the highest activity in NCG (S-type in morphology) 40- to 100-fold greater than the lowest activity in SK-N-DZ (N-type). PCA was not related to 1p abnormalities. After BrdUrd treatment at 5 micrograms/ml for 6 days, PCA increased 6.8-fold in GOTO and 2.7-fold in SK-N-DZ with associated growth inhibition and morphological changes (I-type morphology converted to S-type in GOTO and N-type converted to an advanced N-type in SK-N-DZ). In contrast, only growth suppression was observed in 2 other cell lines, and no changes in PCA, growth or morphology were induced in the remaining 3 cell lines.

MeSH terms

  • Blood Coagulation Factors / analysis*
  • Bromodeoxyuridine / pharmacology
  • Cell Differentiation / drug effects
  • Cell Division / drug effects
  • Chromosome Aberrations*
  • Cysteine Endopeptidases / analysis*
  • Humans
  • Neoplasm Proteins*
  • Neuroblastoma / analysis*
  • Neuroblastoma / genetics
  • Neuroblastoma / pathology
  • Tumor Cells, Cultured

Substances

  • Blood Coagulation Factors
  • Neoplasm Proteins
  • Cysteine Endopeptidases
  • cancer procoagulant
  • Bromodeoxyuridine